(Total Views: 335)
Posted On: 12/19/2019 12:20:35 PM
Post# of 154192
I'm staying in
The greater good is obviously the hugely positive potential leronlimab has for patients and I'm willing to give Averill Powers the benefit of the doubt implementing a culture change at Vyera.
The fact that they only set a $60,000 price instead of double that may mean something about the company's ethics. Although it sounds like they may be boxed in with the Daraprim price and forced to keep it high because of the shrinking patient pool.
My only question about Vyera after thinking for a couple of days is whether they have the salesforce to sell a relatively unknown drug. Selling Leronlimab will be harder than Daraprim, which has decades of familiarity with pertinent docs.
I'm at 190,000 shares now and really have the urge to add another 10,000 to finish my buying.
The greater good is obviously the hugely positive potential leronlimab has for patients and I'm willing to give Averill Powers the benefit of the doubt implementing a culture change at Vyera.
The fact that they only set a $60,000 price instead of double that may mean something about the company's ethics. Although it sounds like they may be boxed in with the Daraprim price and forced to keep it high because of the shrinking patient pool.
My only question about Vyera after thinking for a couple of days is whether they have the salesforce to sell a relatively unknown drug. Selling Leronlimab will be harder than Daraprim, which has decades of familiarity with pertinent docs.
I'm at 190,000 shares now and really have the urge to add another 10,000 to finish my buying.
(1)
(0)
